
醫師:治療僅約20分鐘,患者隔天即可出院
中國醫藥大學新竹附設醫院泌尿科醫師蔡正晏說明,透過內視鏡將生物相容性水凝膠填充材料注射至尿道壁,可增加尿道閉合力,治療僅約20分鐘,患者隔天出院,適合應力性尿失禁患者。
AI-generated summary
應力性尿失禁是女性常見的泌尿系統困擾,隨著年齡增長、生育歷程或骨盆底組織鬆弛,咳嗽、打噴嚏、大笑、跑步、運動或搬重物時腹壓增加,尿道無法有效閉合而引發不自主漏尿。
泌尿科醫師蔡正晏說明,微創尿道填充劑注射治療是透過內視鏡將生物相容性的水凝膠填充材料,精準注射至尿道壁的特定位置,藉此增加尿道內腔的閉合力。(記者廖雪茹攝)
〔記者廖雪茹/新竹報導〕「漏尿絕對不是老化後只能默默承受的宿命!」一名67歲個性開朗的婦女,長期深受「應力性尿失禁」所苦,漸漸的不敢在大庭廣眾之下大笑,甚至減少外出社交,讓親友誤以為她罹患了憂鬱症;所幸在求助泌尿科醫師後,透過僅需20分鐘屬自費的微創尿道填充劑注射治療,就讓她擺脫尿失禁陰霾,重回自信燦爛的笑容。
中國醫藥大學新竹附設醫院泌尿科醫師蔡正晏指出,「應力性尿失禁」是女性非常普遍的泌尿系統困擾。正常狀況下,人體的尿道閉合功能與骨盆底組織能提供足夠支撐,鎖住尿液;但隨著年齡增長、生育歷程或是骨盆底組織逐漸鬆弛,當患者咳嗽、打噴嚏、大笑、跑步、運動或搬重物等,導致腹壓突然增加時,尿道便無法有效閉合,因而引發不自主漏尿。
許多女性常認為「年紀大了漏尿很正常」,或因害羞而難以啟齒,長期依賴護墊隱忍。蔡正晏強調,當漏尿問題開始限制患者的日常生活、運動意願,甚至是社交活動時,它所衝擊的不僅是生理健康,更嚴重侵蝕了個人的自信心與生活品質。
針對治療方式,蔡正晏說明,傳統多以吊帶手術來支撐尿道,而該名患者則是接受了「Bulkamid尿道填充劑注射治療」。這是一種微創且侵入性較低的治療選項,醫師透過內視鏡將生物相容性的水凝膠填充材料,精準注射至尿道壁的特定位置,藉此增加尿道內腔的閉合力。
微創尿道填充劑注射治療之術前術後對比圖。(中醫大新竹附醫提供)
當患者再次因大笑或咳嗽使腹壓上升時,緊閉的尿道便能有效阻擋尿液外漏。相較於傳統吊帶手術,此項注射治療不需置入人工網膜,也沒有大型組織切開與剝離,不僅手術時間僅約20分鐘,還具有傷口極小、術後出血風險低、疼痛感輕微等優勢,患者術後隔天即可出院,並迅速恢復日常生活。
不過,蔡正晏提醒,並非所有類型的尿失禁都適用填充劑治療,醫師會根據患者的漏尿型態、嚴重程度及尿道功能進行全方位評估;部分個案術後也可能需要依狀況進行追加注射,以達到最佳的改善效果。

In response to the problem of elderly people with dementia who refuse to eat, Xinying Hospital promotes "hand-held meals" to design meals into small portions that are easy to take and preserve the dignity of the elderly's independent eating. Doctors pointed out that food refusal may be related to forgetting eating steps, difficulty in operating tableware, depression and suicide risk, and requires integrated care from neurology, psychiatry, nursing, nutrition and swallowing rehabilitation teams.

Chen Baiyue, a gastrointestinal and hepatobiliary physician at Chiayi Christian Hospital, pointed out that dual immunotherapy has been included in health insurance benefits as one of the treatment options for advanced liver cancer. By combining two immune checkpoint inhibitors to activate the autoimmune system, about 20% of patients can have their tumors significantly shrunk or even reversed to the stage of surgical resection, and are less likely to suffer side effects of liver damage.

The Diabetes Health Education Society plans to invite domestic societies to jointly publish Asia's first special guidelines on the side effects of slimming injections with Japan, South Korea and other Asian countries. The first draft is expected to be drafted by the end of November and published in international academic journals in January next year. The content covers situations such as drug withdrawal before surgery, dose conversion and overdose management.

According to statistics from the Food and Drug Administration, this year it received 63 reports of suspected adverse reactions to GLP-1 receptor agonist drugs, of which 39 were for weight loss and 24 were for diabetes treatment. Most of the symptoms were gastrointestinal diseases. The Food and Drug Administration has required pharmaceutical manufacturers to develop post-marketing safety research plans and risk assessment and control plans, and reminds the public that such injections are prescribed by doctors and should not be purchased and administered on their own.

The Taiwan Diabetes Education Association plans to work with domestic and regional partners to develop Asia's first GLP-1 drug side effect prevention and management guidelines, covering safe use in weight loss and diabetes management, which are expected to be published in international academic journals in January next year. Taiwan's Food and Drug Administration has received 63 reports of suspected adverse reactions involving GLP-1 receptor agonists this year, mainly gastrointestinal problems.

A study led by Queen Mary, University of London found that after the new drug baxdrostat was used to treat patients with primary aldosteronism, some patients' blood pressure returned to normal after stopping the drug for up to two years, which is expected to "cure" hypertension. The findings were published in the New England Journal of Medicine and NICE is assessing whether the drug should be made available on the NHS.